Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 16, 2025 02:30 ET | Source: Cantoni Therapeutics

Cantoni Therapeutics secures financing to advance novel non-incretin obesity drug into IND enabling phase

Brabant Development Agency (BOM) and angel investor join lead investor Libertatis Ergo Holding (LEH) in providing funding, with additional financial support from Brabant Startup Fund (BSF)Cantoni...
September 11, 2025 11:00 ET | Source: Zealand Pharma

SAVE THE DATE: Zealand Pharma to host Capital Markets Day in London on December 11, 2025

Press release – No.13 / 2025 SAVE THE DATE: Zealand Pharma to host Capital Markets Day in London on December 11, 2025 Copenhagen, Denmark, September 11, 2025 - Zealand Pharma A/S (Nasdaq: ZEAL)...
September 04, 2025 09:54 ET | Source: PMGC Holdings Inc.

Northstrive Biosciences Announces Completion of Phase II of AI Development Program with YuvaBio Using MitoNova™ Artificial Intelligence (AI) Platform to Develop Therapies for Obesity and Cardiometabolic Diseases

Northstrive Biosciences Announces Completion of Phase II of AI Development Program with YuvaBio Using MitoNova™ Artificial Intelligence (AI) Platform to De
September 02, 2025 05:41 ET | Source: Research and Markets

Microbiome Therapeutics Market Revenues to Double by 2030 - Key Opportunities Lie in Live-biotherapeutics, Personalized Medicine, and Digital Health Integrations

Dublin, Sept. 02, 2025 (GLOBE NEWSWIRE) -- The "Microbiome Therapeutics Market by Products (Fecal Microbiota Transplantation, Live-Biotherapeutics, Microbiome Drugs), Therapeutic Area (Autoimmune...
August 27, 2025 08:05 ET | Source: Kailera Therapeutics, Inc.

Kailera Therapeutics to Participate in Upcoming Investor Conferences

Kailera Therapeutics announced participation in upcoming investor conferences.
August 13, 2025 09:00 ET | Source: ZyVersa Therapeutics

ZyVersa Therapeutics Reports Second Quarter 2025 Financial Results and Highlights Key Near-term Value-building Milestones

KEY HIGHLIGHTS First clinical site for Phase 2a clinical trial for Cholesterol Efflux Mediator™ VAR 200 in patients with diabetic kidney disease (DKD) was activated June 2025; patient screening...
August 12, 2025 07:00 ET | Source: NodThera

NodThera Demonstrates Reversal of Neuroinflammation and Inflammation in Parkinson’s Disease with Oral NLRP3 Inhibitor

NodThera Demonstrates Reversal of Neuroinflammation and Inflammation in Parkinson’s Disease with Oral NLRP3 Inhibitor Phase 1b/2a study results published in Movement Disorders journalOral,...
August 05, 2025 16:05 ET | Source: Biomea Fusion, Inc.

Biomea Fusion Reports Second Quarter 2025 Financial Results and Corporate Highlights

Three presentations at ADA 2025 highlighted the therapeutic potential of icovamenib across multiple aspects of metabolic health: In patients with type 2 diabetes (T2D) not achieving glycemic...
July 22, 2025 08:00 ET | Source: UMeWorld Limited

UMeWorld Positions DAGola™ for Strong Q4 Revenue Surge with U.S. E-Commerce and China Market Expansion

UMeWorld positions DAGola™ for Q4 revenue growth with U.S. e-commerce launch and China rollout; clinically proven oil taps functional nutrition demand.
July 21, 2025 07:00 ET | Source: NodThera

NodThera Announces Appointment of Dr. Jyothis George as Chief Medical Officer

NodThera Announces Appointment of Dr. Jyothis George as Chief Medical Officer Former Amgen, Novo Nordisk and Boehringer Ingelheim senior leader joins NodThera Leadership TeamWill spearhead clinical...